ATE210455T1 - Vwf propeptide enthaltendes pharmazeutisches präparat - Google Patents

Vwf propeptide enthaltendes pharmazeutisches präparat

Info

Publication number
ATE210455T1
ATE210455T1 AT98929378T AT98929378T ATE210455T1 AT E210455 T1 ATE210455 T1 AT E210455T1 AT 98929378 T AT98929378 T AT 98929378T AT 98929378 T AT98929378 T AT 98929378T AT E210455 T1 ATE210455 T1 AT E210455T1
Authority
AT
Austria
Prior art keywords
pharmaceutical preparation
preparation containing
vwf propeptide
containing vwf
propeptide
Prior art date
Application number
AT98929378T
Other languages
English (en)
Inventor
Hans-Peter Schwarz
Katalin Varadi
Peter Turecek
Hendrik Coenraad Hemker
Suzette Lucette Beguin
Original Assignee
Baxter Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Ag filed Critical Baxter Ag
Application granted granted Critical
Publication of ATE210455T1 publication Critical patent/ATE210455T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98929378T 1997-05-28 1998-05-26 Vwf propeptide enthaltendes pharmazeutisches präparat ATE210455T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0091797A AT405485B (de) 1997-05-28 1997-05-28 Eine das vwf-propeptid enthaltende pharmazeutische präparation
PCT/EP1998/003090 WO1998053848A1 (en) 1997-05-28 1998-05-26 PHARMACEUTICAL PREPARATION COMPRISING vWF PROPEPTIDE

Publications (1)

Publication Number Publication Date
ATE210455T1 true ATE210455T1 (de) 2001-12-15

Family

ID=3502803

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0091797A AT405485B (de) 1997-05-28 1997-05-28 Eine das vwf-propeptid enthaltende pharmazeutische präparation
AT98929378T ATE210455T1 (de) 1997-05-28 1998-05-26 Vwf propeptide enthaltendes pharmazeutisches präparat

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT0091797A AT405485B (de) 1997-05-28 1997-05-28 Eine das vwf-propeptid enthaltende pharmazeutische präparation

Country Status (10)

Country Link
US (2) US7005502B1 (de)
EP (1) EP0977584B1 (de)
JP (1) JP4335978B2 (de)
AT (2) AT405485B (de)
AU (1) AU744643B2 (de)
CA (1) CA2288737A1 (de)
DE (1) DE69802918T2 (de)
ES (1) ES2168766T3 (de)
NO (1) NO324064B1 (de)
WO (1) WO1998053848A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047547A1 (en) * 1999-12-24 2001-07-05 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Medicinal compositions for preventing and treating hemorrhagic diseases associating thrombopathy
JP4663837B2 (ja) * 1999-12-24 2011-04-06 一般財団法人化学及血清療法研究所 第▲ｖｉｉｉ▼因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物
CA2591852A1 (en) 2004-12-27 2006-07-06 Baxter International Inc. Polymer-von willebrand factor-conjugates
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
CA2647314A1 (en) 2006-03-31 2007-11-08 Baxter International Inc. Pegylated factor viii
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
CN105816858B (zh) 2007-12-28 2024-10-18 武田药品工业株式会社 重组vwf配方
ES2298096B1 (es) 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
EP2349314B1 (de) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilisierte rekombinante vwf-formulierungen
CA2741634A1 (en) * 2008-10-27 2010-06-03 Baxter International Inc. Models of thrombotic thrombocytopenic purpura and methods of use thereof
AU2010284116B9 (en) 2009-08-20 2015-03-26 Takeda Pharmaceutical Company Limited Purification of VWF for increased removal of non-lipid enveloped viruses
US20110150843A1 (en) * 2009-10-30 2011-06-23 National Institute Of Immunology Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
NL2017452A (en) 2015-10-02 2017-04-11 Asml Netherlands Bv Metrology method and apparatus, computer program and lithographic system
US20190091298A1 (en) 2017-07-07 2019-03-28 Baxalta Incorporated Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf
CA3069295A1 (en) 2017-07-07 2019-01-10 Baxalta Incorporated Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
CA3094644A1 (en) 2018-03-21 2019-09-26 Baxalta Incorporated Separation of vwf and vwf propeptide by chromatographic methods
US12128090B2 (en) 2019-02-01 2024-10-29 Takeda Pharmaceutical Company Limited Methods of prophylactic treatment using recombinant VWF (rVWF)
US20220401524A1 (en) 2019-09-11 2022-12-22 Takeda Pharmaceutical Company Limited Methods of treatment related to complexes of von willebrand factor and complement c1q
KR20220150303A (ko) 2020-02-04 2022-11-10 다케다 야쿠힌 고교 가부시키가이샤 재조합 vwf의 투여에 의한 중증 폰 빌레브란트병 환자의 월경과다 치료

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT350726B (de) 1976-08-30 1979-06-11 Immuno Ag Verfahren zur herstellung einer blut- gerinnungsfoerdernden praeperation aus menschlichem blutplasma
AT368883B (de) 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
AT378005B (de) 1983-08-20 1985-06-10 Linde Ag Verfahren zum desoxidieren von metallschmelzen
AT389815B (de) 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
AT390560B (de) 1986-05-30 1990-05-25 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
US5849536A (en) * 1990-03-02 1998-12-15 Bio-Technology General Corp. Cloning and production of human von willebrand factor GPIb binding domain polypeptides and methods of using same
FR2673632A1 (fr) * 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
AT402891B (de) 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
AT398079B (de) 1991-11-04 1994-09-26 Immuno Ag Präparation mit thrombinaktivität sowie verfahren zu ihrer herstellung
WO1994013329A1 (de) 1992-12-16 1994-06-23 Immuno Aktiengesellschaft Verfahren zur herstellung eines virussicheren biologischen präparates
AT402788B (de) 1993-08-03 1997-08-25 Immuno Ag Virussichere blutgerinnungsfaktor xiii-präparation
JPH07330797A (ja) * 1994-05-31 1995-12-19 Sumitomo Metal Ind Ltd 新規細胞接着活性ペプチド
DE4437544A1 (de) * 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
US6068838A (en) 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase
AT404359B (de) 1996-04-29 1998-11-25 Immuno Ag Gereinigte multimerase
AT404554B (de) 1996-04-29 1998-12-28 Immuno Ag Pharmazeutische präparation

Also Published As

Publication number Publication date
ES2168766T3 (es) 2002-06-16
US7557188B2 (en) 2009-07-07
EP0977584B1 (de) 2001-12-12
US7005502B1 (en) 2006-02-28
WO1998053848A1 (en) 1998-12-03
NO995843D0 (no) 1999-11-29
AU7915698A (en) 1998-12-30
CA2288737A1 (en) 1998-12-03
AT405485B (de) 1999-08-25
JP4335978B2 (ja) 2009-09-30
NO995843L (no) 2000-01-27
ATA91797A (de) 1999-01-15
EP0977584A1 (de) 2000-02-09
NO324064B1 (no) 2007-08-06
US20060003921A1 (en) 2006-01-05
DE69802918T2 (de) 2003-04-10
JP2001527579A (ja) 2001-12-25
DE69802918D1 (de) 2002-01-24
AU744643B2 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
ATE210455T1 (de) Vwf propeptide enthaltendes pharmazeutisches präparat
DE69822665D1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
NO179531C (no) Fremgangsmåte for brönnbehandling
DE69616333D1 (de) Thip zur behandlung von schlafstörungen
DE3772429D1 (de) Pharmazeutisches praeparat zur behandlung von peridontalkrankheiten.
EA199700170A1 (ru) Способ получения некоторых азациклогексапетидов
ATA76995A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
ATE239474T1 (de) Verwendung von levobupivacain
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
ATE493978T1 (de) Behandlung von autoimmunerkrankungen
PT93959A (pt) Processo para a preparacao de derivados de sacarina uteis como inibidores proteoliticos de enzima
ATE202483T1 (de) Immuntolerante prothrombinkomplex-präparation
EP1274414A4 (de) Nasale verabreichung von mitteln zur behandlung von gastroparese
DE3681642D1 (de) Benzopyran-verbindungen zur behandlung von inkontinenz.
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE223721T1 (de) Edelfosin zur behandlung von hirntumoren
DE69736180D1 (de) Behandlung von manischen erkrankungen
ATE126437T1 (de) Verwendung von depogen zur behandlung von eingeschränktem blutkreislauf.
NO995132D0 (no) Fremgangsmåte for reduksjon av fibrinogen
DK0795008T3 (da) Humane hypertrofe chondrocyt-cellelinjer
DE68926222D1 (de) Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen
NO984198L (no) FremgangsmÕte for behandling av aggresjon
ES2120573T3 (es) 24-epi-1-alfa-hidroxivitamina d2 para tratar la osteoporosis.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification